Two views of AI in drug discovery: biological world model versus research process orchestrator

A post contrasts genomics researchers’ view of AI as a “biological world model” with medicinal chemists’ view of it as a “research process orchestrator.” Octant CEO Sri Kosuri says Octomind ranked 20 compounds for follow-up, but its choices haven’t yet been shown to improve a drug program. A computational chemist says AI has shifted his time from choosing and installing tools to asking research questions.